Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
February 09, 2023 07:30 ET
|
Kura Oncology, Inc.
– Phase 1 trial showed 30% CR rate among 20 NPM1-mutant AML patients treated at recommended Phase 2 dose – – Phase 2 registration-directed trial expected to enroll 85 patients in the U.S. and Europe...
Acute Myeloid Leukemia Diagnostics Market Set to Reach Valuation of USD 5,866.25 Million by 2030, Size, Share, Demand, Future Growth, Challenges and Competitive Analysis
January 23, 2023 07:50 ET
|
Data Bridge Market Research
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research Published Latest Acute Myeloid Leukemia Diagnostics Market Study by in-depth analysis of the current scenario, the Market...
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
December 10, 2022 10:30 ET
|
Kura Oncology, Inc.
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated...
Acute Myeloid Leukemia Market Size to Surpass US$ 4.31 Billion by 2030 - Growth Plus Reports
October 19, 2022 06:13 ET
|
Growth Plus Reports
Pune, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global acute myeloid leukemia market is expected to clock US$ 4.31 billion by 2030 and to...
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis: 60+ Leading Companies are Working to Improve the Treatment Landscape
September 06, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis: 60+ Leading Companies are Working to Improve the Treatment Landscape DelveInsight’s...
Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting
April 04, 2022 10:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today two...
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia
March 09, 2022 16:01 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-Only Digital Therapeutic for Acute Myeloid Leukemia
January 06, 2022 16:02 ET
|
Blue Note Therapeutics
SAN FRANCISCO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced...
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
December 13, 2021 08:00 ET
|
Aprea Therapeutics
60% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplantMedian overall survival of 20.6 months BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Aprea...
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia
November 22, 2021 12:20 ET
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE PHASE I/II TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AB8939 IS A NEW...